FDA to review Acadia’s Nuplazid drug to treat Parkinson’s disease psychosis
The meeting will be held on 29th March. Last November, the FDA classified the Nuplazid NDA as having priority review status with a target prescription drug user fee
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.
Preclinical studies of RAD1901 have shown consistent and robust single agent anti-tumor activity in multiple wild type and ESR1-mutant breast cancer models and tumor regression when combined with